COVID-19 and SARS-CoV-2

Initial Viral Entry and Replication

• SARS-CoV-2 enters host cells via the angiotensin-converting enzyme 2 (ACE2) receptor, which serves as the primary cellular portal of entry
• The spike (S) protein on the viral envelope binds ACE2 with extremely high affinity (10-20 fold higher than SARS-CoV), explaining rapid transmissibility
• Transmembrane protease serine 2 (TMPRSS2) facilitates S protein cleavage and membrane fusion, allowing viral internalization
• Once internalized, viral RNA is translated by host ribosomes to produce viral proteins, including RNA-dependent RNA polymerase (RdRp), which enables high-fidelity viral genome replication
• ACE2 is highly expressed on respiratory epithelial cells (particularly type II pneumocytes), endothelial cells, enterocytes, myocardial tissue, and central nervous system neurons—explaining the multi-organ tropism of SARS-CoV-2

Direct Viral Cytopathology and Epithelial Injury

• Productive viral infection of respiratory epithelium causes syncytia formation, apoptosis of infected cells, and loss of epithelial barrier integrity
• Type II pneumocytes are particularly vulnerable; their destruction impairs pulmonary surfactant production and alveolar fluid clearance via downregulation of the sodium-potassium pump (Na+/K+-ATPase)
• Direct endothelial infection triggers endotheliitis characterized by endothelial cell apoptosis, increased vascular permeability, and activation of the coagulation cascade
• Viral proteases (3CLpro and PLpro) degrade host antiviral proteins and suppress interferon (IFN) signaling, allowing unchecked viral replication in early infection

Aberrant Host Immune Response and Cytokine Storm

• Rather than mounting a balanced antiviral response, severely infected individuals develop innate immune overactivation with massive release of pro-inflammatory cytokines and chemokines (IL-6, TNF-α, IL-1β, IP-10/CXCL10, MCP-1/CCL2)
• This cytokine storm is driven by pattern recognition receptor (PRR) activation on macrophages and dendritic cells, particularly by engagement of TLR3 and RIG-I sensing viral RNA
• Paradoxically, early innate immune responses are often blunted in severe COVID-19—the virus effectively evades initial detection, and when overwhelming immune activation finally occurs, it is often too late for effective viral clearance and instead causes bystander tissue damage
• Massive neutrophil infiltration into lungs releases neutrophil extracellular traps (NETs), proteolytic enzymes, and reactive oxygen species, causing additional epithelial damage and promoting a prothrombotic state
• Th1/Th17 skewing occurs with relative suppression of Th2 and regulatory T cell (Treg) responses, promoting tissue-damaging inflammation

Coagulation Abnormalities and Thrombosis

• Viral endotheliitis, platelet activation, and extreme elevations in pro-thrombotic mediators (tissue factor, von Willebrand factor, P-selectin) create a hypercoagulable state
• Microthrombi form in pulmonary, cerebral, and systemic vasculature; autopsy studies reveal widespread venous and arterial thrombosis
• Elevated D-dimer (often 2-10 fold normal) reflects ongoing thrombin generation and fibrin deposition
• Pulmonary embolism (PE) and disseminated intravascular coagulation (DIC) occur in severe cases, contributing to respiratory failure and death

ACE2-Renin-Angiotensin System (RAS) Dysregulation

• Viral binding and internalization of ACE2 downregulates surface ACE2 expression, reducing its protective function
• ACE2 normally converts angiotensin II (Ang II) to angiotensin 1-7 (Ang 1-7), which opposes Ang II's pro-inflammatory, pro-fibrotic, and pro-thrombotic effects
• Loss of ACE2 activity allows Ang II accumulation, exacerbating lung inflammation, increasing vascular permeability, promoting fibrosis, and driving systemic hypertension
• This explains why ACE inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) may paradoxically be protective (maintaining alternative Ang 1-7 pathways)

Acute Respiratory Distress Syndrome (ARDS) Development

• Severe COVID-19 pneumonia progresses to ARDS through loss of alveolar epithelial barrier function, increased vascular permeability, neutrophilic infiltration, and hyaline membrane formation
• Unlike typical ARDS, early COVID-19 ARDS features preserved lung compliance ("happy hypoxia"—severe hypoxemia with relatively normal lung mechanics), attributed to ventilation-perfusion (V/Q) mismatch and intrapulmonary shunting rather than diffuse consolidation
• Progressive disease involves increased fibrosis with decreased compliance, increased dead space, and worsening gas exchange

Multi-Organ Dysfunction Mechanisms

• Myocarditis: Direct myocardial viral invasion combined with cytokine-mediated inflammation; elevated troponin correlates with poor prognosis
• Acute kidney injury (AKI): Direct tubular epithelial infection (ACE2 is highly expressed on proximal tubule cells), hypoxic injury, cytokine-mediated inflammation, and thrombotic microangiopathy
• Hepatic injury: Direct viral infection of hepatocytes and cholangiocytes; cytokine-mediated inflammation; bile duct dysfunction
• Thrombotic stroke: Hypercoagulability combined with endothelial inflammation and ACE2-mediated cerebrovascular effects
• Central nervous system (CNS) involvement: Viral entry via hematogenous dissemination or retrograde axonal transport; direct neuronal infection; blood-brain barrier disruption; cytokine-mediated neuroinflammation

Post-Acute Sequelae of COVID-19 (PASC/Long COVID)

• Mechanisms remain incompletely understood but likely involve: (1) persistent viral antigen or RNA in sequestered tissue compartments, (2) viral reactivation or coinfection with latent viruses (EBV, CMV), (3) autoimmune activation with production of cross-reactive antibodies against self-antigens, (4) microvascular thrombosis and endothelial dysfunction, and (5) mitochondrial dysfunction and metabolic derangements
• Chronic inflammatory markers (elevated IL-6, CRP) persist in many PASC patients despite resolution of acute infection

Age as Primary Risk Factor

• Advanced age (≥65 years) is the single most powerful predictor of severe disease and mortality; risk increases exponentially with each decade of life
• Pathophysiologic basis: age-associated immunosenescence (impaired T cell responses, reduced interferon production), diminished epithelial barrier function, increased baseline inflammation ("inflammaging"), higher ACE2 expression in elderly airway epithelium, and decreased capacity for organ system recovery
• Mortality in patients ≥80 years approaches 10-15% compared to <1% in those <50 years

Chronic Medical Conditions

• Diabetes mellitus (particularly if poorly controlled) increases risk 2-3 fold; mechanisms include impaired neutrophil function, enhanced ACE2 expression in diabetic lungs, and dysregulated inflammatory responses
• Cardiovascular disease (hypertension, coronary artery disease, heart failure) increases risk 2-5 fold; myocardial injury in COVID-19 is particularly common and prognostically significant in this group
• Chronic lung disease (COPD, asthma, interstitial lung disease) increases risk of severe lower respiratory tract involvement; baseline pulmonary inflammation and reduced reserve worsen outcomes
• Chronic kidney disease and end-stage renal disease (ESRD) increase risk substantially; uremia impairs immune responses, and reduced renal clearance of cytokines amplifies inflammation
• Obesity (BMI ≥30, particularly ≥40) increases risk 2-3 fold through multiple mechanisms: mechanical impairment of respiratory mechanics, altered immune function, chronic inflammation, increased ACE2 expression in adipose tissue, and difficulty with mechanical ventilation

Immunocompromised States

• Primary immunodeficiency, malignancy (particularly hematologic), solid organ transplantation, and HIV infection with CD4 <200 cells/μL dramatically increase risk of severe COVID-19
• Severely immunocompromised patients have prolonged viral shedding (weeks to months), increased risk of immune escape variants, and difficult-to-treat infection
• Biologic immunosuppressive agents (TNF-α inhibitors, IL-6 antagonists, Janus kinase inhibitors) increase risk, though the magnitude varies by agent and whether the underlying condition itself increases risk

Pregnancy

• Pregnancy is an independent risk factor for severe COVID-19 and critical illness; risk is higher in third trimester
• Mechanisms: pregnancy-associated immunologic changes (Th2 shift, regulatory T cell expansion), physiologic respiratory changes (reduced functional residual capacity), and potential placental ACE2-mediated viral effects on fetal-placental unit
• Maternal infection increases risks of preterm birth, preeclampsia, and fetal loss, though vertical transmission is rare

Race and Ethnicity

• Black, Hispanic, and Native American populations experience disproportionately higher rates of infection, hospitalization, and death
• Contributing factors: systemic racial inequities in healthcare access, higher prevalence of comorbidities (diabetes, hypertension, obesity), occupational exposures (essential worker status), housing crowding, and structural barriers to preventive care—NOT genetic susceptibility

Viral Factors

• Variant of concern (VOC) emergence has shaped pandemic trajectory; variants with increased transmissibility (Alpha, Delta, Omicron) spread more rapidly, while some variants show immune escape (Omicron) reducing vaccine efficacy against infection while preserving protection against severe disease
• Viral load at time of testing correlates with symptom severity and transmission risk; higher initial viral loads predict worse outcomes

Cardinal Symptoms (Early Phase)

• Fever (present in 50-90% of symptomatic patients): caused by IL-6, IL-1β, and TNF-α-mediated hypothalamic set-point elevation; typically 38-39°C but can exceed 40°C; often accompanied by chills and myalgia
• Cough (50-80%): initially dry, caused by viral airway epithelial invasion and inflammation; may become productive late in course; relates to tracheal and bronchial involvement
• Dyspnea (30-40% overall but up to 80% in hospitalized patients): results from V/Q mismatch and intrapulmonary shunting in early disease; later reflects pulmonary edema, ARDS, and reduced lung compliance; timing of onset (early vs late) distinguishes primary pulmonary failure from secondary complications
• Fatigue and malaise (50-70%): IL-6 and TNF-α-mediated systemic symptoms; may be profound and persistent
• Headache (8-34%): proposed mechanisms include viral CNS invasion, meningeal inflammation, cytokine-mediated effects, or simply non-specific systemic illness; usually mild to moderate and self-limited

Respiratory Symptoms (Pulmonary Phase)

• Dyspnea progression: typically worsens around day 5-7 as immune activation peaks; patients describe increasing respiratory effort, oxygen desaturation with minimal exertion, and sensation of "chest tightness"
• Hemoptysis (rare, <5%): indicates severe airway inflammation or diffuse alveolar hemorrhage (DAH); associated with poor prognosis
• Sputum production: initially scant, may increase if secondary bacterial infection develops

Systemic Symptoms

• Anosmia and ageusia (loss of smell and taste): occur in 40-60% of early-stage COVID-19; distinct because they often occur in isolation (no nasal congestion) and may precede respiratory symptoms; mechanism involves olfactory neuron infection and anosmia-specific epithelial damage rather than nasal obstruction; reversible in most but can persist for weeks in some patients
• Gastrointestinal symptoms (20-60%): nausea, vomiting, diarrhea, abdominal pain; reflect direct viral infection of intestinal epithelium (high ACE2 expression); fecal viral shedding occurs and may outlast respiratory shedding
• Myalgia and arthralgia (15-20%): IL-1β and IL-6-mediated musculoskeletal inflammation; typically mild but can be severe; may persist into recovery phase

Physical Examination Findings

• Fever: generally present proportional to severity; absence of fever may indicate immune exhaustion in critical illness
• Tachycardia: often present even with mild hypoxemia; reflects systemic inflammation and sympathetic activation
• Tachypnea: more predictive of severity than hypoxemia; respiratory rates >30 at presentation or escalating during hospitalization indicate worsening disease
• Hypoxemia: "happy hypoxia" or silent hypoxemia is a characteristic and paradoxical feature where patients maintain oxygen saturation as measured by pulse oximetry (SpO2) that seems discordant with profound hypoxemia on arterial blood gas (PaO2 can be 40-50 mmHg with SpO2 85-90%); proposed mechanisms include V/Q mismatch from microvascular thrombosis and intrapulmonary shunting without diffuse consolidation, and possible impaired hypoxic ventilatory drive
• Lung auscultation: typically absent or minimal findings despite imaging evidence of pneumonia—"silent chest" without expected crackles is common in early ARDS; when present, bilateral crackles or inspiratory squeaks suggest alveolar involvement or atelectasis
• Cyanosis: indicates critical hypoxemia
• Skin findings: some patients develop erythematous maculopapular rash, petechial rash (suggesting thrombotic complications), livedo reticularis (reticular skin pattern from microvascular thrombosis), or acral cyanosis (blue discoloration of fingers and toes)
• Abdominal examination: may reveal mild

Establishing the diagnosis

• Nucleic acid amplification test (NAAT/RT-PCR): the reference standard; detects SARS-CoV-2 RNA (targets typically N, E, or ORF1ab) from nasopharyngeal, mid-turbinate, or saliva specimens. IDSA diagnostic guidance favors NAAT over antigen testing when sensitivity matters (symptomatic patient, hospitalization, immunocompromise).
• Rapid antigen test: detects nucleocapsid protein; highly specific but substantially less sensitive, particularly early in illness and in asymptomatic persons. A negative antigen test in a symptomatic high-risk patient does not exclude infection — the next step is repeat antigen testing after an interval or confirmatory NAAT (FDA/CDC serial-testing guidance).
• Serology: never for acute diagnosis (antibodies lag by 1–3 weeks). Anti-nucleocapsid antibody implies prior natural infection; anti-spike antibody may reflect vaccination.
• Prolonged PCR positivity after recovery reflects non-viable RNA shedding, not ongoing infectiousness; cycle threshold values should not guide clinical decisions.

Characteristic laboratory findings

• Lymphopenia is the classic hematologic clue and correlates with severity.
• Inflammatory markers: elevated CRP, ferritin, LDH, and IL-6 track with cytokine-driven injury.
• D-dimer: markedly elevated levels identify thrombotic risk and predict mortality.
• Troponin elevation signals myocardial injury and adverse prognosis.

Imaging

• Chest radiograph/CT: bilateral, peripheral, lower-lobe–predominant ground-glass opacities, often with crazy-paving and later organizing-pneumonia patterns. Imaging is for severity assessment and complication detection, not diagnosis (ACR advises against CT as a screening test).

Severity classification (NIH COVID-19 Treatment Guidelines framework)

• Mild: symptoms without dyspnea or abnormal imaging.
• Moderate: lower respiratory disease with SpO₂ ≥94% on room air.
• Severe: SpO₂ <94% on room air, respiratory rate >30, PaO₂/FiO₂ <300, or infiltrates involving more than half the lung.
• Critical: respiratory failure, shock, or multiorgan dysfunction; ARDS is defined by the Berlin criteria.
• In children, consider MIS-C using the CDC case definition (fever, multisystem involvement, inflammation, recent SARS-CoV-2 exposure).

Immediate stabilization

• Oxygen and positioning: titrate supplemental O₂ to a target saturation in the low-to-mid 90s; escalate to high-flow nasal cannula before intubation in hypoxemic respiratory failure, and use awake prone positioning in patients requiring high-flow oxygen (NIH COVID-19 Treatment Guidelines).
• If intubated, apply low tidal volume, lung-protective ventilation (~6 mL/kg predicted body weight) with prone positioning for moderate-to-severe ARDS; ECMO at experienced centers for refractory hypoxemia.

Outpatient, high-risk, not hypoxemic

• Protease (3CLpro/Mpro) inhibitor: nirmatrelvir–ritonavir, first-line when started within 5 days of symptom onset; requires renal dose adjustment and a formal drug-interaction review because ritonavir is a potent CYP3A4 inhibitor.
• Nucleoside analog RdRp inhibitors: IV remdesivir (3-day outpatient course) or, as a last-line alternative, molnupiravir — avoid molnupiravir in pregnancy and in patients of childbearing potential without contraception given mutagenicity concerns.
• Do not give systemic corticosteroids to non-hypoxemic outpatients; steroids in the early viral-replication phase may impair clearance and worsen outcomes.

Hospitalized patients

• Antiviral: remdesivir for those requiring supplemental oxygen, greatest benefit earlier in the course.
• Corticosteroid: dexamethasone 6 mg daily is standard once supplemental oxygen is required — the mortality benefit comes from the RECOVERY trial and is confined to hypoxemic patients.
• Immunomodulator escalation for rapidly increasing oxygen requirement plus systemic inflammation: an IL-6 receptor antagonist (tocilizumab) or a JAK inhibitor (baricitinib), added to dexamethasone.
• Thromboprophylaxis: prophylactic-dose LMWH (e.g., enoxaparin) for all hospitalized patients absent bleeding risk; therapeutic-dose heparin is reasonable in selected non-critically ill patients with elevated D-dimer and low bleeding risk (ASH guidance).

Pulmonary — emergencies

• ARDS: alveolar epithelial and endothelial injury with hyaline membranes; signaled by worsening PaO₂/FiO₂ with bilateral infiltrates not explained by cardiac failure. The leading cause of death.
• Barotrauma (pneumothorax, pneumomediastinum, subcutaneous emphysema): alveolar rupture from high transpulmonary pressures or vigorous spontaneous effort; sudden desaturation with rising airway pressures — emergency.
• Secondary infection: ventilator-associated bacterial pneumonia, and in critically ill or steroid/tocilizumab-treated patients COVID-associated pulmonary aspergillosis; suspect with new fever, purulent secretions, or clinical decline after initial improvement.

Thrombotic — emergencies

• Pulmonary embolism and DVT: endotheliitis, NETs, and tissue factor expression create a hypercoagulable state; abrupt hypoxemia or right heart strain with a sharply rising D-dimer.
• Arterial thrombosis and ischemic stroke: acute focal neurologic deficit warrants immediate stroke pathway activation.

Treatment-related

• Dexamethasone: hyperglycemia, delirium, secondary infection, and Strongyloides hyperinfection in patients from endemic regions.
• Tocilizumab: GI perforation and reactivation of latent TB/hepatitis B; blunted CRP makes infection harder to detect.
• Baricitinib: thrombosis and infection risk.
• Nirmatrelvir–ritonavir: CYP3A4-mediated interactions — statin rhabdomyolysis, calcineurin-inhibitor toxicity.
• Remdesivir: transaminase elevation and bradycardia.
• Heparin: bleeding and heparin-induced thrombocytopenia.

• Isolated anosmia/ageusia without nasal congestion is the classic COVID-19 buzzword; it reflects olfactory support-cell infection, not obstruction, and distinguishes COVID-19 from ordinary rhinovirus coryza.
• "Happy hypoxia": profound hypoxemia with a comfortable-appearing patient and a quiet chest. The single best next step is objective oxygenation assessment (pulse oximetry, ambulatory saturation, ABG) — never reassurance based on how well the patient looks.
• Lymphopenia plus elevated CRP, ferritin, LDH, and D-dimer with bilateral peripheral ground-glass opacities is the classic lab-imaging pairing. Rising D-dimer with sudden desaturation means PE until proven otherwise.
• Dexamethasone only if hypoxemic. The single most-tested management discriminator: steroids reduce mortality in oxygen-requiring patients (RECOVERY) but are not indicated — and may harm — in the non-hypoxemic outpatient, where a protease inhibitor (nirmatrelvir–ritonavir) within 5 days of symptom onset is the answer instead.
• ACE2 is the receptor; TMPRSS2 primes the spike protein. The association examiners love: ACE inhibitors and ARBs should be continued, not stopped, in COVID-19 — a common distractor claims they increase risk.
• Nirmatrelvir–ritonavir is a drug-interaction question in disguise. Ritonavir inhibits CYP3A4; expect a stem about statin-induced rhabdomyolysis or tacrolimus toxicity. Renal impairment requires dose reduction.
• MIS-C appears weeks after infection in a child with fever, rash, conjunctivitis, shock, and coronary dilation — the Kawasaki-like distractor. Check an echocardiogram; treat with IVIG and steroids.
• Do not choose hydroxychloroquine, ivermectin, or azithromycin — IDSA recommends against all three. Similarly, a positive PCR weeks after recovery reflects residual RNA, not reinfection or continued infectiousness.